The microRNA‐204‐5p inhibits APJ signalling and confers resistance to cardiac hypertrophy and dysfunction

• Published in: Clinical and translational medicine Vol. 12; no. 1; pp. e693 - n/a
• Main Authors: Gaddam, Ravinder Reddy, Kim, Young‐Rae, Jacobs, Julia S., Yoon, Jin‐Young, Li, Qiuxia, Cai, Angela, Shankaiahgari, Hamsitha, London, Barry, Irani, Kaikobad, Vikram, Ajit
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.01.2022; John Wiley and Sons Inc; Wiley
• Subjects: Animals; Apelin Receptors - antagonists & inhibitors; Apelin Receptors - metabolism; apelin‐receptor; aplnr; Cardiomegaly - drug therapy; Cardiomegaly - prevention & control; Cardiomyocytes; Clinical medicine; Collagen; Disease Models, Animal; ERK1/2; Genotype & phenotype; Heart Diseases - drug therapy; Heart Diseases - prevention & control; Heart failure; Heart rate; Ischemia; MicroRNAs; MicroRNAs - metabolism; MicroRNAs - pharmacology; microRNA‐204; noncoding RNAs; Rats; Signal Transduction - drug effects; Surgery; heart failure; ERK1/2; aplnr; noncoding RNAs; apelin-receptor; microRNA-204

Background MicroRNAs regulate cardiac hypertrophy development, which precedes and predicts the risk of heart failure. microRNA‐204‐5p (miR‐204) is well expressed in cardiomyocytes, but its role in developing cardiac hypertrophy and cardiac dysfunction (CH/CD) remains poorly understood. Methods: We p...